Navigation Links
Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
Date:8/21/2008

bout Ardea Biosciences, Inc.

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, gout, cancer and inflammatory diseases. We have five product candidates in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, an NNRTI, which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it for clinical development. RDEA594, our lead product candidate for the treatment of gout, is being evaluated in a Phase 1 study. We are currently evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, and have completed a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second-generation MEK inhibitor for the treatment of cancer and inflammatory diseases, RDEA436, in a human micro-dose pharmacokinetic study and have selected it for clinical development.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding our goals, including the expected properties and benefits of RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds and the results of preclinical, clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcome of preclinical
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... YORK , June 1, 2015   ... of Open, Transparent and Connected financial marketplaces for ... Incorporated, a San Diego -based ... traded on OTCQB®, America,s only public venture market ... Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ...
(Date:6/1/2015)... , June 1, 2015 /CNW Telbec/ -  Ergoresearch Ltd ... and known under the « Équilibre, orthèses et ... Ended on March 31, 2015. All dollar amounts in the ... for the third quarter of fiscal year 2015 ended this ... to revenues of $ 3,823,151 for the quarter ended March ...
(Date:6/1/2015)... Columbia and MENLO PARK, Calif. ... Inc. (OTCQX: DMPI) ("DelMar" and the "Company"), a ... therapies in new orphan drug indications, announced that it ... live webcast today, June 1, 2015, at 5:30 p.m. ... data from its Phase I/II study of VAL-083 ...
Breaking Medicine Technology:OTC Markets Group Congratulates OncoSec Medical on NASDAQ Listing 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 2Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 3Third Quarter results - Fiscal 2015 - Ergoresearch reports its results for the quarter ended March 31, 2015 4DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 2DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 3DelMar Pharmaceuticals to Host Investor Conference Call on June 1, 2015 to Discuss New VAL-083 Phase I/II Clinical Data in Patients with Refractory Glioblastoma Multiforme 4
... Novartis Pharmaceuticals Corporation ("Novartis") announced today that ... Drugs Advisory Committee (ODAC) recommended approval of Afinitor® ... advanced neuroendocrine tumors (NET) of pancreatic origin. ... data from the everolimus RADIANT (RAD001 In Advanced ...
... 12, 2011 MSA (NYSE: MSA ), the ... that protect people,s health and safety, announced today that it ... via the Internet on Thursday, April 28, 2011 at 10:00 ... Investors and interested parties will have the opportunity ...
Cached Medicine Technology:Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 2Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 3Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 4Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 5Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 6Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 7Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 8Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 9Novartis Drug Afinitor® Recommended by FDA Oncology Advisory Committee for Approval to Treat Advanced NET of Pancreatic Origin 10MSA Schedules First Quarter Earnings Webcast 2
(Date:6/2/2015)... Join us for a new event in Westwood, New Jersey—the ... , who overcame her brain aneurysm during the summer of ... awareness and funds for brain aneurysm research. , Rhonda ... will be one less case of someone suffering from a ... the 1st Anniversary Awareness Walk in Honor of Rhonda ...
(Date:6/2/2015)... Vancouver, B.C., Canada (PRWEB) June 02, 2015 ... publisher of audit, compliance and risk solutions ... a new online risk management effectiveness gap-improvement program. ... the effect of uncertainty on objectives. Organizations not ... they improve their capabilities to do this (risk ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lynn Lester as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to honor Lynn Lester with this prestigious award,” said ...
(Date:6/1/2015)... Garden City, NY (PRWEB) June 02, 2015 ... honors Lourinda Willey as a 2015-2016 ... Circle. She is recognized with this prestigious distinction for ... is the nation’s leading networking organization exclusively for professional ... operating Local Chapters. , "I’m pleased to present Lourinda ...
(Date:6/1/2015)... City, NY (PRWEB) June 02, 2015 ... honors Selma Tansey as a 2015-2016 inductee ... is recognized with this prestigious distinction for leadership in ... exclusively for professional women, boasting more than 700,000 members ... to present Selma with this important honor," said NAPW ...
Breaking Medicine News(10 mins):Health News:New Awareness Raising Event in Westwood, NJ to Benefit Renowned Brain Aneurysm Foundation 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 2Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 3Health News:Specialty Technical Publishers and Radar Launch Online Assessment Program for Evaluation of Risk Management Effectiveness 4Health News:National Association of Professional Women Inducts Lynn Lester, Director of Clinical Operations/CEO, Recovery Treatment Center, Into its VIP Woman of the Year Circle 2Health News:National Association of Professional Women Inducts Lourinda Willey, Owner and Principal of Lourinda R. Willey LLC, Into its VIP Professional Woman of the Year Circle 2Health News:NAPW Inducts Selma Tansey, Executive Director of Washington Communities Human Services, Into its VIP Professional Woman of the Year Circle 2
... in alpha-linoleic acid reduced cardiac events in Asian people at ... in South Asian people, especially if they move to the ... by conventional risk factors,// like diabetes and high blood pressure. ... with the effect of a Mediterranean type diet on cardiac ...
... to a major medical study by researchers it is ... The latest from researchers in Denmark, observe that people ... lesser risk of developing dementia and Alzheimer's disease. People ... benefit. ,The researchers are realistic about their research. ...
... than a placebo when it comes to the relief of ... at the Mayo Clinic, the majority of people with muscle ... relieved// by ionized bracelets. So the researchers divided the participants ... ionized bracelet, while the other received a placebo bracelet that ...
... doing exercise improves your cholesterol profile, even in the ... shown how exercise affects the level of 'good' and ... the body attached to protein molecules, the combination being ... (LDL or 'bad' cholesterol) are linked to heart disease, ...
... person aged 40 or over has a lifetime risk of ... they have high blood pressure. Heart failure is an increasing ... within the heart which makes it hard to pump blood ... the condition is very disabling. ,Researchers for the ...
... survival of criticare patients gets better if specialists in ... Hopkins and Pittsburgh University have analysed the evidence on ... found that patients do much better if they are ... in critical care medicine. ,Previous research has ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: